Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
74.46%
-
Total 13F principal
-
$221,348,000
-
Principal change
-
+$2,056,250
-
Total reported market value
-
$166,426,000
-
Number of holders
-
30
-
Value change
-
+$82,162
-
Number of buys
-
11
-
Number of sells
-
13
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q3 2019
As of 30 Sep 2019,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
30 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$221,348,000
in principal (par value) of the bond.
The largest 10 bondholders included
DLD Asset Management, LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, CNH PARTNERS LLC, DeepCurrents Investment Group LLC, GOLDMAN SACHS GROUP INC, Allianz Asset Management GmbH, and Worth Venture Partners, LLC.
This page lists
30
institutional bondholders reporting positions
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.